Verrica Pharmaceuticals Inc
Company Profile
Business description
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
Contact
44 West Gay Street
Suite 400
West ChesterPA19380
USAT: +1 484 453-3300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
76
Stocks News & Analysis
stocks
3 charts on Anthropic’s historic IPO filing
stocks
Weight loss drugs not an existential threat to undervalued ASX share
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,971.40 | 2.60 | 0.03% |
| CAC 40 | 7,889.60 | 2.46 | 0.03% |
| DAX 40 | 25,692.22 | 101.45 | 0.40% |
| Dow JONES (US) | 52,538.00 | 160.43 | 0.31% |
| FTSE 100 | 10,691.02 | 4.48 | 0.04% |
| HKSE | 23,094.83 | 53.51 | 0.23% |
| NASDAQ | 26,469.74 | 8.07 | -0.03% |
| Nikkei 225 | 63,954.19 | 685.82 | 1.08% |
| NZX 50 Index | 13,691.33 | 11.06 | 0.08% |
| S&P 500 | 7,738.53 | 15.93 | 0.21% |
| S&P/ASX 200 | 8,847.30 | 2.80 | -0.03% |
| SSE Composite Index | 3,681.47 | 33.17 | 0.91% |